anti-v3 monoclonal antibodies display broad neutralizing activities against multiple hiv-1 subtypesanti-v3单克隆抗体显示广泛的中和活动对多个hiv - 1亚型.pdf

Anti-V3 Monoclonal Antibodies Display Broad Neutralizing Activities against Multiple HIV-1 Subtypes 1,2 3 4 5 5 5 Catarina E. Hioe *, Terri Wrin , Michael S. Seaman , Xuesong Yu , Blake Wood , Steve Self , Constance 1 1 1,2 Williams , Miroslaw K. Gorny , Susan Zolla-Pazner 1 Department of Pathology, New York University Langone School of Medicine, New York, New York, United States of America, 2 Veterans Affairs New York Harbor Healthcare System, New York, New York, United States of America, 3 Monogram Biosciences, Inc., South San Francisco, California, United States of America, 4 Department of Medicine, Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America, 5 Public Health Sciences Division, Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America Abstract Background: The V3 loop of the HIV-1 envelope (Env) glycoprotein gp120 was identified as the ‘‘principal neutralizing domain’’ of HIV-1, but has been considered too variable to serve as a neutralizing antibody (Ab) target. Structural and immunochemical data suggest, however, that V3 contains conserved elements which explain its role in binding to virus co- receptors despite its sequence variability. Despite this evidence of V3 conservation, the ability of anti-V3 Abs to neutralize a significant proportion of HIV-1 isolates from different subtypes (clades) has remained controversial. Methods: HIV-1 neutralization experiments were conducted in two independent labor